Fair pricing of innovative medicines: An EHA position paper

Anton Hagenbeek, John Gribben, Ulrich Jäger, Peter Kapitein, Giampaolo Merlini, Maria Piggin, Carin A. Uyl-De Groot, Robin Doeswijk*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
Original languageEnglish
Article numberA125
JournalHemaSphere
Volume4
Issue number5
DOIs
Publication statusPublished - 2020

Bibliographical note

Funding Information:
AH: Consultancy for Takeda Oncology USA. Chair of EHA Task Force on Fair Pricing/EU Affairs Committee. JG: Research funding from AstraZeneca, Celgene, Janssen. PI of clinical trials: Roche/Genentech, AstraZeneca, Janssen, AbbVie, BeiGene, Epizyme, Gilead/Kite, Merck, Takeda, TG Therapeutics. Honoraria from AbbVie, AstraZeneca, BMS, Gilead, Janssen, Roche, Novartis, Merck, Karypharm, Morphosys. UJ: Employment/ consultation for Novartis, Roche. Grants/pending grants from AbbVie, Bioverativ/BMS, Celgene, Gilead, Janssen, Novartis, Roche, Takeda-Millennium. PK: Employment with Central Bank of the Netherlands. GM: The author reports no relevant financial disclosures. MP: Employment with Imperial College London. Grants (to PNH Support) from Apellis Pharmaceuticals. CUdG: Unrestricted grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Gilead, Novartis, AstraZeneca, Roche. RD: Employment at EHA Executive Offices.

Cite this